Evidence map›Paper›PMID 32228581›Full record

Observational studyRespiratory research2020

Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort.

Jerome Bouquet, David E Tabor, Jonathan S Silver, Varsha Nair, Andrey Tovchigrechko, M Pamela Griffin, Mark T Esser, Bret R Sellman, Hong Jin

Registry-linked trialAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05315674 (Early Diagnostic BioMARKers in Exacerbations of COPD), which is not on this map. Cited by 48 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05315674 unknown statusnot on this mapstarted 2022, after this paper: background citation

Early Diagnostic BioMARKers in Exacerbations of COPD: the MARKED Study

TypeobservationalSponsorCenter of Expertise for Chronic Organ FailureRan2022 to 2025Enrolled150ConditionsCOPD, COPD ExacerbationArmsFrequent assessment of biomarker panel
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Microbiota Emergencies in the Diagnosis of Lung Diseases: A Meta-Analysis.Frontiers in cellular and infection microbiology · 2021
    Pooled it
  3. Long-Term Risk of Mortality Associated with Isolation ofInternational journal of chronic obstructive pulmonary disease
    Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Why the COPD Microbiome Matters: How Airway Microbes Shape Disease Severity and Treatment Response.International journal of chronic obstructive pulmonary disease · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Review
  17. Macrophages and the microbiome in chronic obstructive pulmonary disease.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jerome BouquetClinical Pharmacology & Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, South San Francisco, USA. jerome.bouquet@astrazeneca.com.
David E TaborClinical Pharmacology & Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, South San Francisco, USA.
Jonathan S SilverRespiratory Inflammation and Autoimmunity, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.
Varsha NairClinical Pharmacology & Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, South San Francisco, USA.
Andrey TovchigrechkoData Science and AI, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.
M Pamela GriffinRespiratory Inflammation and Autoimmunity, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.
Mark T EsserMicrobial Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.
Bret R SellmanMicrobial Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.
Hong JinClinical Pharmacology & Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, South San Francisco, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) is a heterogeneous disease characterized by frequent exacerbation phenotypes independent of disease stage. Increasing evidence shows that the microbiota plays a role in disease progression and severity, but long-term and international multicenter assessment of the variations in viral and bacterial communities as drivers of exacerbations are lacking.

methodsTwo-hundred severe COPD patients from Europe and North America were followed longitudinally for 3 years. We performed nucleic acid detection for 20 respiratory viruses and 16S ribosomal RNA gene sequencing to evaluate the bacterial microbiota in 1179 sputum samples collected at stable, acute exacerbation and follow-up visits.

resultsSimilar viral and bacterial taxa were found in patients from the USA compared to Bulgaria and Czech Republic but their microbiome diversity was significantly different (P < 0.001) and did not impact exacerbation rates. Virus infection was strongly associated with exacerbation events (P < 5E-20). Human rhinovirus (13.1%), coronavirus (5.1%) and influenza virus (3.6%) constitute the top viral pathogens in triggering exacerbation. Moraxella and Haemophilus were 5-fold and 1.6-fold more likely to be the dominating microbiota during an exacerbation event. Presence of Proteobacteria such as Pseudomonas or Staphylococcus amongst others, were associated with exacerbation events (OR > 0.17; P < 0.02) but more strongly associated with exacerbation frequency (OR > 0.39; P < 4E-10), as confirmed by longitudinal variations and biotyping of the bacterial microbiota, and suggesting a role of the microbiota in sensitizing the lung.

conclusionsThis study highlights bacterial taxa in lung sensitization and viral triggers in COPD exacerbations. It provides a global overview of the diverse targets for drug development and explores new microbiome analysis methods to guide future patient management applications.

Indexed as

AgedAged, 80 and overBacteriaBacterial LoadDisease ProgressionEuropeFemaleHumansIncidenceLongitudinal StudiesLungMaleMiddle AgedPulmonary Disease, Chronic ObstructiveRetrospective StudiesRisk Factors

Identifiers

PMID32228581
PMCPMC7104712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.